University of Kentucky

UKnowledge
Pharmaceutical Sciences Faculty Publications

Pharmaceutical Sciences

8-22-2011

Histone Deacetylase Inhibitors and Mithramycin A Impact a
Similar Neuroprotective Pathway at a Crossroad between Cancer
and Neurodegeneration
Sama F. Sleiman
Burke-Cornell Medical Research Institute

Jill Berlin
Burke-Cornell Medical Research Institute

Manuela Basso
Burke-Cornell Medical Research Institute

Saravanan S. Karuppagounder
Burke-Cornell Medical Research Institute

See next page for additional authors

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/ps_facpub
Part of the Pharmacy and Pharmaceutical Sciences Commons

Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar
Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration
Digital Object Identifier (DOI)
http://dx.doi.org/10.3390/ph4081183

Notes/Citation Information
Published in Pharmaceuticals, v. 4, no. 8, p. 1183-1195.
This is an open access article distributed under the Creative Commons Attribution License which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.

Authors
Sama F. Sleiman, Jill Berlin, Manuela Basso, Saravanan S. Karuppagounder, Jürgen Rohr, and Rajiv R.
Ratan

This article is available at UKnowledge: https://uknowledge.uky.edu/ps_facpub/33

Pharmaceuticals 2011, 4, 1183-1195; doi:10.3390/ph4081183
OPEN ACCESS

Pharmaceuticals
ISSN 1424-8247
www.mdpi.com/journal/pharmaceuticals
Article

Histone Deacetylase Inhibitors and Mithramycin A Impact a
Similar Neuroprotective Pathway at a Crossroad between
Cancer and Neurodegeneration
Sama F. Sleiman 1,2,*, Jill Berlin 1, Manuela Basso 1,2, Saravanan S.Karuppagounder 1,2,
Jürgen Rohr 3 and Rajiv R. Ratan 1,2,*
1

2

3

Burke-Cornell Medical Research Institute, 785 Mamaroneck Ave, White Plains, New York,
NY 10605, USA
Department of Neurology and Neuroscience, Weill Medical College of Cornell University, 525 E.
68th St., New York, NY 10065, USA
Department of Pharmaceutical Sciences, University of Kentucky, 789 S. Limestone St., Lexington,
KY 40536, USA

* Authors to whom correspondence should be addressed; E-Mails: ssleiman@burke.org (S.F.S.);
rrr2001@med.cornell.edu (R.R.R.); Tel.: +1-914-368-3121 (S.F.S.); +1-914-597-2851 (R.R.R.);
Fax: +1-914-597-2225 (S.F.S.); +1-914-597-2225 (R.R.R.).
Received: 25 July 2011; in revised form: 11 August 2011 / Accepted: 15 August 2011 /
Published: 22 August 2011

Abstract: Mithramycin A (MTM) and histone deacetylase inhibitors (HDACi) are
effective therapeutic agents for cancer and neurodegenerative diseases. MTM is a FDA
approved aureolic acid-type antibiotic that binds to GC-rich DNA sequences and interferes
with Sp1 transcription factor binding to its target sites (GC box). HDACi, on the other
hand, modulate the activity of class I and II histone deacetylases. They mediate their
protective function, in part, by regulating the acetylation status of histones or transcription
factors, including Sp1, and in turn chromatin accessibility to the transcriptional machinery.
Because these two classes of structurally and functionally diverse compounds mediate
similar therapeutic functions, we investigated whether they act on redundant or synergistic
pathways to protect neurons from oxidative death. Non-protective doses of each of the
drugs do not synergize to create resistance to oxidative death suggesting that these distinct
agents act via a similar pathway. Accordingly, we found that protection by MTM and
HDACi is associated with diminished expression of the oncogene, Myc and enhanced
expression of a tumor suppressor, p21waf1/cip1. We also find that neuroprotection by MTM

Pharmaceuticals 2011, 4

1184

or Myc knockdown is associated with downregulation of class I HDAC levels. Our results
support a model in which the established antitumor drug MTM or canonical HDACi act via
distinct mechanisms to converge on the downregulation of HDAC levels or activity
respectively. These findings support the conclusion that an imbalance in histone acetylase
and HDAC activity in favor of HDACs is key not only for oncogenic transformation, but
also neurodegeneration.
Keywords: mithramycin A; HDAC inhibition; Myc; neurons; oxidative stress

1. Introduction
Extensive studies from cell culture and human postmortem tissue reveal a mechanistic connection
between oncogenesis and acute and chronic neurodegeneration in the CNS. The ability of transforming
stimuli (e.g., SV40 T antigen) to induce death of neurons led to the notion that clonal expansion that
normally accompanies carcinogenesis in dividing cells has been supplanted by clonal deletion in post
mitotic neurons to avoid tumors from disrupting CNS circuitry during aging [1,2]. Support for this
concept has grown as many classical anti-tumor compounds such as mithramycin A (MTM) and
histone deacetylase inhibitors (HDACi) have been shown to be broadly effective in rodent models of
neurological disease.
MTM is a gene selective Sp1 inhibitor that has long been used as a chemotherapeutic agent. Its use
was highlighted in a screen for compounds effective in inhibiting tumor cell growth without affecting
normal cells [3]. It is also neuroprotective in vitro and in vivo models of neurodegeneration [4-8]. It
rapidly enters into the cells, binds to GC rich DNA sequences, thus displacing the Sp1 transcription
factor from its binding sites on the promoters of oncogenes such as Myc to inhibit their expression.
These effects contribute to its ability to kill cancer cells as well as protect neurons against toxic insults.
Indeed, we have recently shown that MTM mediated knockdown of oncogenes including Myc protects
against oxidative stress-mediated neuronal death in vitro or in fly and rodent models of Huntington’s
disease in vivo [2].
HDACi are small molecules that interfere with the ability of histone deacetylases (HDAC) to
remove acetyl groups from histones and other cellular proteins. They are classified into several groups
based on their chemical structure and which HDAC class they target. For example, butyrate, apicidin
and MS-275 are structurally diverse compounds that selectively inhibit Class I HDACs [9], which
includes the predominantly nuclear HDACs: HDAC1, HDAC2, HDAC3 and HDAC8. The dynamic
state of chromatin and the accessibility of gene promoters to the transcriptional machinery are
dependent on the balance between histone acetyltransferase (HAT) and HDAC activity. Defects in the
regulation in the interplay between HAT and HDAC function can lead to development of many
cancers as well as to neurodegenerative disease. For example, HDAC2 and HDAC3 are over-expressed
in multiple forms of cancer [10-13], and contribute as well to neurodegeneration [14-16]. HDACi are
not only therapeutically effective against cancer, but they are moving toward human clinical trials for
neurodegeneration [17,18] and stroke [17-20].
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Considering the effectiveness of both MTM and HDACi in killing cancer cells but protecting
neurons, we investigated whether they protect against oxidative stress-induced neuronal death by
targeting a convergent pathway. Indeed, we show that it is not only sufficient to inhibit the Class I
nuclear HDACs to mediate neuroprotection against oxidative stress, but also that the pathways targeted
by HDACi and MTM are overlapping. Specifically, protection both MTM and HDACi is associated
with inhibition of the expression of the oncogene Myc and induction of the tumor suppressor
p21waf1/cip1. We also show that MTM or Myc knockdown can inhibit the expression of class I HDACs.
Our results suggest that MTM and HDACi target pathways that converge at the intersection of cancer
and neurodegeneration.
2. Experimental Section
Cell Culture: Immature primary cortical neurons were obtained from fetal Sprague Dawley rats
[embryonic day 17 (E17)] as previously described [21].
Cell Viability: For cytotoxicity studies, immature primary cortical neurons (E17) were isolated as
described above and plated at a density of one million cells/mL in 96-well plates. The next day, cells
were rinsed with warm PBS and then placed in medium containing the glutamate analogue HCA
(5 mM). HCA was diluted from 100-fold concentrated solutions that were adjusted to pH 7.5. MTM
(7.5 nM or 300 nM), mithramycin SDK (SDK; 7.5 nM or 75 nM), sodium butyrate (50 µM or 5 mM),
TSA (0.66 μM), apicidin (10 nM) and MS-275 (100 nM) were added at the time of HCA treatment and
were present throughout the experiment. MTM and sodium butyrate were prepared as 10 mM or 0.5M
solutions respectively and serial dilutions were used to arrive to the desired concentration. The next
day, cell viability was assessed by the MTT assay (Promega) [22]. 1way ANOVA followed by the
Dunnett post test was used to measure statistical significance. p < 0.05 was considered to be
statistically significant.
RNA extraction and Real Time PCR: Total RNA was prepared from immature primary cortical
neurons (E17) using the NucleoSpin RNA II Kit (MACHEREY-NAGEL) according to the
manufacturer’s protocol. Real-time PCRs were performed as a duplex reaction using a Myc
(Rn00561507_m1), p21waf1/cip1 (Rn01427989_s1), HDAC1 (Rn02114316_gH), HDAC2
(Rn01193634_g1), HDAC3 (Rn00584926_m1) and HDAC8 (Rn01419050_m1) gene expression assay
(Applied Biosystems), which use a FAM-labeled probe, and a β-actin gene expression assay, which
uses a VIC-labeled probe (Applied Biosystems) so that gene amplification could be normalized to
β-actin. These experiments were performed using a 7500 Real Time PCR System (Applied
Biosystems) using standard PCR protocol and amplification conditions. One-way ANOVA followed
by the Dunnett post test were performed to measure statistical significance. p < 0.05 was considered to
be statistically significant.
Immunoblot analysis: Whole cell proteins were extracted in RIPA-B buffer (1% Triton X-100, 1%
SDS, 50 mM Tris-Cl, pH 7.4, 500 mM NaCl and 1 mM EDTA). Samples were boiled in Laemmli
buffer and electrophoresed under reducing conditions on NuPAGE® Novex 4–12% Bis-Tris Gel
polyacrylamide gels (Invitrogen). Proteins were transferred to a nitrocellulose membrane (Bio-Rad) by
electroblotting. Nonspecific binding was inhibited by incubation in Odyssey blocking buffer (LI-COR
Biosciences). Antibodies against c-Myc (1472-1; Epitomics), p21waf1/cip1 (OP-76; Calbiochem),
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HDAC1 (PA1-860; Thermo Scientific), HDAC2 (1603-1; Epitomics), HDAC3 (2246-1; Epitomics),
HDAC8 (sc-11405; Santa Cruz Biotechnology) and β-actin (AC-74; Sigma-Aldrich) were diluted
1:1000, 1:1000; 1:2000; 1:2000; 1:1000; 1:1000 and 1:10,000, respectively, in odyssey blocking buffer
and the membranes were incubated overnight at 4 °C. Fluorophore-conjugated Odyssey IRDye-680 or
IRDye-800 secondary antibody (LI-COR Biosciences) was used at 1:10,000 dilution followed by
incubation for 1 hour at room temperature. Finally, proteins were detected using an Odyssey infrared
imaging system (LI-COR Biosciences).
Myc ShRNA know down: Two Myc (NM_012603) ShRNA clones (TRCN0000039641: 5' AAACC
CAGGGCTGCCTTGGAAAAG 3' and TRCN0000039641: 5' AAACCCAGGGCTGCCTTGGAA
AAG 3'; Open Biosystems) and Non-Target shRNA Control Vector (Sigma) were introduced into
immature primary cortical neurons (E17) using the Amaxa Rat neuron Nucleofector Kit as directed by
the manufacturer’s protocol (Lonza). The next day, Myc knockdown was confirmed by whole cell
lysate western blots.
Statistical Analysis: 1way or 2way ANOVA followed by the Dunnett or Bonferroni post tests
respectively were used to measure statistical significance. p < 0.05 was considered to be statistically
significant.
3. Results
MTM and HDACi protect the central nervous system (CNS) from both chronic and acute insults.
For example, they are among the most effective therapeutic compounds tested to date in animal models
of Huntington’s disease [2,5,18,23] as well as in stroke [17,19,20]. Because oxidative stress is a feature
of most neurodegenerative diseases, we utilized an in vitro model of neuronal oxidative death to test
whether these two structurally divergent classes of antitumor compounds are neuroprotective via
similar mechanisms. When immature cortical neurons (E17) are continuously exposed to glutamate [or
a glutamate analogue, homocysteic acid (HCA)], they die via competitive inhibition of cystine
transport [21]. Reduced intracellular cyst(e)ine leads to depletion of the antioxidant glutathione. Cell
death attributable to glutathione depletion has features of apoptosis and can be completely prevented
by classical antioxidants [21]. MTM (300 nM), its more potent and less toxic structural analog SDK
(75 nM), sodium butyrate (5 mM), apicidin (10 nM), and MS-275 (100 nM)} protect post mitotic
cortical neurons from oxidative stress-induced neuronal death (Figure 1A). They appear to mediate
neuroprotection by normalizing the transcriptional profile of neurons in response to oxidative stress [2]
(data not shown). Specifically, MTM promotes neuroprotection, in part, by inhibiting the expression of
oncogenes such as Myc and by promoting the expression of tumor suppressors such as p21waf1/cip1. This
is due to its ability to displace the Sp1 transcription factor from its binding sites (GC boxes) on the
promoter of Myc without affecting its binding to the promoter of p21waf1/cip1 [2]. Sodium butyrate,
apicidin and MS-275, on the other hand, are class I selective HDAC (HDAC1, 2, 3 and 8) inhibitors.
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Figure 1. MTM, sodium butyrate, apicidin and MS-275 protect immature cortical neurons
against oxidative death by targeting overlapping pathways.

(A): MTM (300 nM), SDK (75 nM, the MTM analog that binds to DNA), sodium butyrate (5 mM),
apicidin (10 nM) and MS-275 (100 nM) protect immature primary cortical neurons (E17) from
oxidative stress, whereas PreB (300 nM, the MTM analog that does not bind to DNA) does not.
(B and C): No increase in cell survival is detected in response to oxidative stress in cells treated
with sub-protective doses of MTM (B) or its SDK analog (C) along with sub-protective doses of
sodium butyrate. Statistical analysis was conducted by 1way ANOVA followed by the Dunnett post
test. Significant levels compared to HCA (5 mM) treatment alone. * p < 0.05; and ** p < 0.01; and
*** p < 0.0001. Cell survival experiments were repeated three times.

To determine whether there is a convergence in the protective pathways targeted by these
compounds, we treated immature cortical neurons with sub-protective doses of MTM (7.5 nM) or its
analog SDK (7.5 nM) plus sodium butyrate (50 µM) and assessed neuronal survival in response to
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oxidative stress. This strategy was utilized in previous work that identified combinatorial treatments
for Huntington’s Disease flies [24]. We expected to observe an additive effect on survival if these
compounds promote protection via independent parallel pathways; on the other hand, if converging
pathways are affected, no such additive protection should be observed. Indeed, treatment of neurons
with threshold doses of MTM or its analog SDK plus sodium butyrate does not increase the survival of
neurons exposed to oxidative stress as compared to either compound alone suggesting the protective
pathways may be convergent (Figures 1B and C).
To elucidate putative mechanisms by which the protective pathways converge, we first tested
whether like MTM, HDAC inhibition affected Myc and p21waf1/cip1levels. We have previously shown
that MTM induced p21waf1/cip1and repressed Myc levels and that these changes partially contribute to
MTM’s protective effect [2]. Indeed, we find that like MTM, HDAC inhibition reduced Myc
expression (Figures 2A, C and D) and induced p21waf1/cip1expression (Figures 2B, C and D). Both of
these genes are regulated by Sp1 binding to target sites in their promoter. To understand whether the
change in Myc and p21waf1/cip1 expression in response to HDACi involves alterations of Sp1 occupancy
at their respective promoters, we performed chromatin immunoprecipitation studies. Previously, we
have shown that HDACi treatment induces Sp1 acetylation in rat embryonic cortical neurons and
increases Sp1 binding to GC boxes in electromobility shift assays [23]. We observe that HDACi
treatment only increased Sp1 occupancy at the p21waf1/cip1promoter, but did not affect its binding to the
Myc promoter (Figures 2E and F). These results are in agreement with Sp1 being an activator at the
p21waf1/cip1 promoter [25,26]. Our results suggest that while HDACi downregulate Myc protein
expression, they do not affect Sp1 occupancy at the Myc promoter. Thus, HDACi may negatively
affect another transcription factor to modulate Myc expression or alternatively act
post-transcriptionally to decrease the stability of the protein. Nevertheless, these experiments
demonstrate that like MTM, HDAC inhibition negatively modulates the oncogene Myc and positively
affects the tumor suppressor p21waf1/cip1 in post mitotic neurons.
HDACs are believed modulate tumor progression by silencing tumor suppressor genes. We wanted
to know whether the antitumor drug MTM negatively modulated HDAC levels and whether this could
explain the convergence with pharmacological HDACi and underlie some of the protective effects of
this antitumor drug in post mitotic neurons. Indeed, we found that MTM treatment affects HDAC
expression levels. We treated cells with protective doses of MTM (300 nM) as well as with the
non-protective structural analog PreB (300 nM) and performed Real Time PCR monitored message
levels for the class I HDACs. We focused our attention on class I HDACs since inhibitors of this class
were sufficient to protect neurons against oxidative stress-induced death (Figure 1A). MTM treatment
did not significantly affect HDAC1 and HDAC3 mRNA levels (Figures 3A and C), whereas it
significantly reduced HDAC2, and HDAC8 mRNA levels (Figures 3B and D). As expected, the
non-protective analog PreB did not have any significant effect on the expression of any of these
HDACs. We next investigated whether the changes in the expression of these HDACs translated to the
protein level. Interestingly, even though MTM treatment only significantly affected HDAC2 and
HDAC3 protein levels, we observe a similar trend in reduction of expression with HDAC1 and
HDAC8 (Figure 3E and F). To determine whether MTM can act as a global HDACi, we tested whether
treatment with protective doses of this compound affects global histone H3 acetylation and in turn
general chromatin accessibility to transcription factors.
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Figure 2. HDACi like MTM reduce the expression of the Myc oncogene and promote the
expression of the p21waf1/cip1 tumor suppressor.

(A) Real Time RTPCR analysis reveals that TSA (0.66 µM) significantly inhibits Myc expression
levels; and (B) induces p21waf1/cip1 expression levels; (C) Western blots reveal that both sodium
butyrate (5 mM) and TSA (0.66 µM) treatment reduces Myc protein levels and induces p21waf1/cip1
protein levels; (D) Quantification of the Western blots reveals that the effects on Myc and
p21waf1/cip1 levels are significant. (E and F) Chromatin immunoprecipitation experiments show that
HDACi have no effect on Sp1 occupancy on the Myc promoter, whereas they significantly induce
it at the p21waf1/cip1 promoter. Treatments were conducted for five hours and the experiments were
repeated three times. Statistical analysis was conducted by 1way ANOVA followed by the Dunnett
post test. Significant levels compared to control treatment alone. * p < 0.05; and ** p < 0.01; and
*** p < 0.0001.
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Figure 3. MTM affects class 1 HDAC expression levels.

Real time RTPCR shows that MTM (300 nM) does not significantly affect HDAC1 (A) and
HDAC3 (C) expression levels; whereas it significantly reduces HDAC2 (B) and HDAC8 (D)
expression levels. These changes covary with neuroprotection by MTM as the non-protective
analog PreB (300 nM) has no effect on the expression of these genes. Cells were treated for five
hours and the experiments were repeated three times. (E): Western Blots show that MTM treatment
reduces the protein levels of class 1 HDACs. (F): Quantification of three different western blots
reveals that only HDAC2 and HDAC3 protein levels are significantly affected by MTM treatment.
(G): Unlike sodium butyrate (5 mM) and TSA (0.66 µM), MTM does not induce acetylation of
histone H3. For the western blot experiments, cells were treated with the compounds for 48 hours
and experiments were repeated three times. Statistical analysis was conducted by 1way ANOVA
followed by the Dunnett post test. Significant levels compared to control treatment alone.
*: p < 0.05 and **: p < 0.01 and ***: p < 0.0001.

We find that unlike HDACi (TSA and sodium butyrate) that MTM did not increase global histone
H3 acetylation (Figure 3G). This result is in agreement with our observation that only a subset of the
HDAC proteins is significantly affected by MTM. In addition, we can’t rule out an effect of MTM on
HAT expression. Taken together, these studies suggest that MTM and sodium butyrate protect neurons
from oxidative stress by normalizing similar transcriptional responses in neurons. This is achieved in
part by reducing HDAC protein levels and function as well as by reducing the expression of oncogenes
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(e.g., Myc) and inducing the expression of tumor suppressor genes (e.g., p21cip1/waf1). The two
identified mechanisms are most likely linked as HDACs are recruited to the promoters of these two
genes [27,28]. In addition, Myc has been reported to regulate the expression of some HDAC genes
including HDAC2 [29].
Previously, we have shown that Myc inhibition protects neuron from oxidative stress-induced
death [2]; however, the mechanism through which this protection occurs remained elusive. Considering
protective doses of MTM affected the expression of class 1 HDACs whereas the non-protective analog
PreB did not and that these same protective doses inhibited Myc expression, we decided to test
whether knock down of Myc affected HDAC expression levels. Indeed, we find that like MTM, Myc
inhibition leads to a reduction in class I HDAC protein levels (Figure 4). This suggests that Myc
regulation of HDAC expression contributes to its toxic effect in neurons exposed to oxidative
stress. This is particularly relevant in the case of HDAC2 [15] and HDAC3 [14,30] already shown to
be sufficient to induce toxicity in models of neurodegeneration and to negatively affect plasticity for
brain recovery.
Figure 4. MTM affects class 1 HDAC expression levels.

(A) Western blot analysis reveals that Myc knockdown using ShRNA significantly affects class I
HDAC protein levels. (B) Quantification of Western blots. Statistical analysis was conducted by
1way ANOVA followed by the Dunnett post test. Significant levels compared to control shRNA
alone. * p < 0.05; and ** p < 0.01; and *** p < 0.0001.

4. Discussion
MTM is not only a FDA approved chemotherapeutic agent, but also one of the most
neuroprotective agents in vitro [2,4] and in vivo [2,5]. It mediates neuroprotection by inhibiting Sp1
binding to it target sites in the promoters of oncogenes such as Myc, without affecting its binding to
the promoters of tumor suppressors such as p21waf1/cip1 [2]. Considering that both MTM and HDACi
inhibit cancer cell growth as well protect post-mitotic neurons against multiple stresses including
oxidative stress and DNA damage [2,4,20,23], we decided to test whether these two classes of
compounds mediate their functions by affecting similar or independent pathways. We show that MTM
and the class 1 HDACi sodium butyrate protect cells by targeting similar pathways (Figure 1). Indeed,
HDACi inhibit the expression of the Myc oncogene and induce the p21waf1/cip1 tumor suppressor
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(Figures 2A–D). The induction of p21waf1/cip1 expression occurs by inducing binding of the Sp1
activator to its site in the p21waf1/cip1 promoter (Figure 2F); on the other hand, HDACi treatment does
not affect Sp1 binding on the Myc promoter. There are multiple Sp1 sites in the Myc promoter. We
only tested the ones that have previously been shown to be responsive to MTM treatment [2]. It
remains possible that Sp1 binding to different sites may be modulated by HDACi treatment.
Alternatively, HDACi may affect Myc expression independent of Sp1. Results from cancer cell lines
reveal that sodium butyrate inhibits Myc expression and implicate HDAC3 in this process. Indeed,
both sodium butyrate and stable knockdown of HDAC3 in colon cancer cells leads to reduction in Myc
levels by stimulating membrane localization of β-catenin, a Wnt pathway effector whose nuclear
localization is necessary for Myc expression [27]. Recent evidence from rat cortical neurons also
reveals that HDACi can cause cellular redistribution and reorganization of corepressor complexes [31].
Alternatively, HDACi may mediate Myc down-regulation by modulating the acetylation status of p53
and its DNA binding [32].
The overlap between the pathways targeted by MTM and HDACi does not end with the modulation
of Myc and p21waf1/cip1 levels. MTM treatment affects the expression level of HDACs themselves at
multiple levels (Figure 3). For example, a reduction in the protein levels of all class 1 HDACs is
observed with protective doses of MTM even though the reduction is only significant for HDAC2 and
HDAC3. These two HDACs are particularly interesting because they mediate neuronal degeneration
and death in multiple paradigms. HDAC2 negatively modulates memory formation and synaptic
plasticity [15]. Indeed, neurotrophic factors such as BDNF stimulate S-nitrosylation of HDAC2. This
in turn leads to its release from the promoters of genes leading to chromatin remodeling and to
activation of genes involved in neuronal development [33]. Moreover, HDAC2 interacts with ATM
and inhibits its function leading to neuronal cell cycle reentry and degeneration in ataxia [34].
Similarly, HDAC3 mediates toxicity in a Caenorhabditis elegans model of Huntington’s Disease [30] as
well as in in vitro models of neuronal oxidative death [14]. HDAC3 is also a negative regulator of
long-term memory formation [16,35]. One interesting observation is the lack of correlation between the
MTM induced changes in HDAC mRNA and protein levels. For example, only HDAC2 is significantly
reduced at both the mRNA and protein levels. HDAC1 and 3 are not transcriptionally affected, yet we
observe a decline in protein levels suggesting that MTM might regulate these HDACs at posttranscriptional or translational level. Even though, MTM treatment affects the expression of multiple
HDACs, it does not affect global histone acetylation (Figure 3G). These results however don’t negate
the potential of locus specific and modification specific changes such as increases in the acetylation of
histone H4-K12 as observed in HDAC3 knockdowns [27]. In addition, even though our results
highlight the neuroprotective benefit of inhibiting class I HDAC activity or protein levels, they do not
rule out the importance of class II HDACs in neuron death. Indeed, inhibition of HDAC6 protects
immature cortical neurons from oxidative stress mediated death and promotes regeneration [36].
Our results highlight the complexity of interaction between Myc and HDACs in cells. We find that
HDACi not only affect Myc expression, but also that Myc reduction inhibits all class 1 HDACs. This
can happen at multiple levels. Myc has been shown to transcriptionally activate the expression of
HDAC2 [13,29]. How it affects the rest of the identified HDACs remains to be determined. In
addition, in agreement with this complexity, our results reveal that HDACi not only affect HDAC
activity in the cells, but through their regulation of Myc levels, they also affect HDAC protein levels.
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Our studies highlight the intersection between the pathways that mediate cancer and
neurodegeneration. Indeed, we provide support for the notion that both HDACi and MTM promote
neuroprotection by inhibiting the expression or functions of proteins that mediate transformation such
as Myc, HDAC1, HDAC2 and HDAC3 [2,10-13] and by promoting the expression of tumor
suppressors such as p21waf1/cip1.
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